Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Scinai Immunotherapeutics ( (SCNI) ) has issued an announcement.
On December 22, 2025, Scinai Immunotherapeutics Ltd. held its Annual Meeting of Shareholders, where investors approved a series of corporate governance and compensation measures. Shareholders re-elected director Mark Germain to serve until the third annual meeting after the current one; approved an amendment to the Articles of Association to increase the number of authorized ordinary shares, potentially expanding Scinai’s capacity for future equity issuance; and endorsed long‑term equity incentives for Chief Executive Officer Amir Reichman and several directors, including new option grants and accelerated vesting for two former directors stepping down as part of cost‑cutting efforts. Investors also approved a grant of ADSs to a long-serving officer, and ratified the appointment of Zvi Haft, a BDO member firm, as the company’s auditor for 2025, collectively signaling shareholder support for the current leadership, restructuring steps, and financial oversight framework.
Spark’s Take on SCNI Stock
According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.
Scinai Immunotherapeutics is undergoing a financial recovery but faces significant challenges such as negative cash flows and high debt levels. The stock shows neutral technical indicators, suggesting moderate market confidence. Its attractive valuation might appeal to value investors, but the absence of dividends and financial risks may deter more conservative investors.
To see Spark’s full report on SCNI stock, click here.
More about Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is an Israel-based biotechnology company focused on developing immunotherapy-related products, with its headquarters at the Jerusalem BioPark on the Hadassah Ein Kerem Campus in Jerusalem. The company’s shares trade in the form of American Depositary Shares (ADSs), each representing 4,000 ordinary shares, and it operates as a foreign private issuer under U.S. securities regulations.
Average Trading Volume: 71,583
Technical Sentiment Signal: Sell
Current Market Cap: $673.9K
For an in-depth examination of SCNI stock, go to TipRanks’ Overview page.